Skip to main content

Table 3 Clinico-pathological characteristics of the study group

From: Functional polymorphisms in the promoter regions of MMP2 and MMP3 are not associated with melanoma progression

Variable*

Patients

%

Gender

  

   Males

573

57.2

   Females

429

42.8

Family History

  

   Yes

167

16.7

   No

826

82.4

   Unknown

9

0.9

Multi-primary Melanoma

  

   Yes

152

15.2

   No

849

84.7

   Unknown

1

0.1

Stage at Diagnosis

  

   0

58

5.8

   I

504

50.3

   II

235

23.4

   III

169

16.9

   IV

9

0.9

   Unstagable¥

27

2.7

Current Stage

  

   0

56

5.6

   I

435

43.4

   II

159

15.9

   III

217

21.7

   IV

129

12.9

   Unstagable¥

6

0.5

Primary Clark Level

  

   I

58

5.8

   II

108

10.8

   III

150

14.9

   IV

489

48.8

   V

69

6.9

   Unknown

128

12.8

Thickness (mm)

  

   In situ

58

5.8

   < 1.01

321

32.0

   1.01 – 2.00

272

27.1

   2.01 – 4.00

161

16.1

   > 4.00

121

12.1

   Unknown

69

6.9

Tumor Infiltrating Lymphocytes (TILs)

  

   Absent

206

20.6

   Non-brisk

397

39.6

   Brisk

31

3.1

   unknown

368

36.7

Distant Metastasis

  

   Yes

130

13.0

   No

870

86.8

   N/Aϕ

2

0.2

Intransit Metastasis

  

   No

942

94.0

   Yes

27

2.7

   N/Aϕ

33

3.3

Number of Moles

  

   None

260

25.9

   Few

498

49.7

   Moderate

169

16.9

   Many

40

4.0

   N/Aϕ

35

3.5

Phenotypic Index

  

   1 (low risk)

38

3.8

   2

210

21.0

   3

317

31.6

   4

328

32.7

   5 (high risk)

105

10.5

   N/Aϕ

4

0.4

Site of the Primary Melanoma

  

   Extremities

535

53.4

   Trunk

342

34.1

   Head and Neck

71

7.1

   Non-cutaneousω

12

1.2

   Unknown

42

4.2

  1. * With the exception of 'current stage', the variables were recorded at the initial diagnosis.
  2. ¥ patients with missing data on the 'T' classification.
  3. ω 90% mucosal melanomas and 10% other sites.
  4. Ï• N/A: data not available.